ThromboGenics touts Phase II eye therapy results

ThromboGenics says that a mid-stage trial of microplasmin demonstrated positive results for a back-of-the-eye disease. And researchers said that the safety profile of the drug was so good that they decided to recruit an additional 15 patients to test a higher dosage of the drug. They will present their data at the annual meeting of the American Society of Retina Specialists.

- take a look at this release
- here's the AFX report on the data

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.